Your missing links are here (17 April 2020)
By: Rasmus Kragh Jakobsen - Apr. 17, 2020
Top Picks
- Testing and speed are essential for stopping the COVID19 pandemic. Thursday the first CRISPR-based COVID19 detection technology was published by Charles Chui in Nature Biotechnology and is much faster than the standard method. Also here.
- Here is an overview of two teams developing CRISPR-based detection of COVID19.
- And if You just need one stop the Data Journalism team at the Financial Times do a fantastic job of crunching the numbers.
More COVID19
- CRISPR pioneer Jennifer Doudna opens lab to run Covid-19 tests.
Old-school video-game PACMAN gets a whole new twist. In a Cell pre-proof scientist at Stanford have developed a CRISPR-Cas13 strategy for shredding COVID19 in human lung epithelial cells.
Video interview with CRISPR and genomics-pioneer George Church on COVID19, future trends and more.
Research
- A CRISPR-based assay for the detection of opportunistic infections from simple urine sampling is a quick and easy way to monitor immunosuppressed kidney transplant patients. Published in Nature Biomedical Engineering.
- A study in Nature Chemical Biology led by CRISP-pioneer Emmanuelle Charpentier narrows CRISRP-Cas9 precision down to two groups of arginines in the Cas9 endonuclease.
- Symptoms in ALS Mouse Model Improve with CRISPR Base Editing according to a study in Molecular Therapy.
Reviews
- Recent review on multiplexing CRISPR technologies for gene editing
Industry
Avectas just raised $20 million to accelerate its novel non-viral delivery platform for gene modified cell therapy products.
Cellectis' new patent widen it's TALEN-based technology for developing universal CAR-T cells for immunotherapies to CRISPR-Cas9-based tech.
Evotec Makes Move into Gene Therapy with Takeda Deal
Heh, huh, wow
- Could a rogue scientist use CRISPR to conjure another pandemic?
- Informative infographic: How to overcome the challenges of gene therapy manufacturing.
CRISPR gene editing spotlight by the "congressional watchdog," GAO (The U.S. Government Accountability Office).
Tags
CLINICAL TRIALS
Sickle Cell Disease, SCD, and Transfusion Dependent Beta-Thalassemia, TDT, (NCT06363760)
Sponsors:
Editas Medicine, Inc.
Sponsors:
Editas Medicine, Inc.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III